ImmunoGen soars as armed antibody heads toward a possible registration study

Waltham, MA-based ImmunoGen ($IMGN) is reporting early signs of success for its armed antibody mirvetuximab soravtansine (IMGN853), which sent its stock up 19% in early trading on Monday. One of the pioneers in the development of antibody drug conjugates, ImmunoGen has been working on a new ADC for FRα-positive platinum-resistant ovarian cancer which zeroes in on this cancer and then drops a highly toxic payload on the target. Among 17 evaluable patients in their early study of this therapy, 9--or 53%--had an objective response to the therapy and 6 of them were still responding at the time of the data cutoff. And Charles Morris, the company's chief development officer, says that the biotech has a shot at a near-term application to the FDA. "We're preparing to initiate a Phase II trial in late 2015 that will assess this ADC as a single-agent treatment for patients with FRα-positive platinum-resistant ovarian cancer. It is possible that this trial could be used for registration in this patient population," Morris noted in a statement. Release

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Months after approving a COVID-19 shot based on early data, Russia is reporting data from nearly 19,000 people showing it is more than 90% effective.

Early-stage biotech Elevian has raised $15 million as it looks to target multiple age-related diseases.

A month after seeing a "robust immune response" from a clutch of RSV vaccine hopefuls, GlaxoSmithKline is kicking off a key late-stage test.